Conference item : Abstract

Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Preiss, D., Herrington, W., & Haynes, R. (2022). Empagliflozin and cardiovascular outcomes in patients with chronic kidney disease: the EMPA-KIDNEY trial. 146(25), E577–E577.

MLA Style

Preiss, D., et al. Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: the EMPA-KIDNEY Trial. no. 25, American Heart Association, 2022, pp. E577–E577.

Chicago Style

Preiss, D, W Herrington, and R Haynes. 2022. “Empagliflozin and Cardiovascular Outcomes in Patients with Chronic Kidney Disease: the EMPA-KIDNEY Trial.” In , 146:E577–E577. American Heart Association.
Share
Print

Access Document

Files:: Preiss_et_al_2022_Empagliflozin_and_cardiovascular.pdf

(Preview, Accepted manuscript, pdf, 109.6KB, Terms of use)

Publisher copy:: 10.1161/CIR.0000000000001116

Authors

+ Preiss, D More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Nuffield Department of Population Health
Sub department:: Clinical Trial Service Unit
Role:: Author
ORCID:: 0000-0003-3139-1836

+ Herrington, W More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Nuffield Department of Population Health
Sub department:: Clinical Trial Service Unit
Role:: Author

+ Haynes, R More by this author

Institution:: University of Oxford
Division:: MSD
Department:: Nuffield Department of Population Health
Sub department:: Clinical Trial Service Unit
Role:: Author
ORCID:: 0000-0002-1179-0023

Publisher:: American Heart Association
Journal:: Circulation More from this journal
Volume:: 146
Issue:: 25
Pages:: E577-E577
Publication date:: 2022-12-19
Event title:: American Heart Association Scientific Sessions 2022
Event location:: Chicago, IL, USA
Event website:: https://sessions.hub.heart.org/aha-22
Event start date:: 2022-11-05
Event end date:: 2022-11-07
DOI:: 10.1161/CIR.0000000000001116
EISSN:: 1524-4539
ISSN:: 0009-7322

Language:: English
Keywords:: sodium glucose co-transporter 2 inhibitors

chronic kidney disease

cardiovascular disease
Subtype:: Abstract
Pubs id:: 1333283
Local pid:: pubs:1333283
Deposit date:: 2024-02-06

Terms of use

Copyright holder:: American Heart Association, Inc.
Copyright date:: 2022
Rights statement:: © 2022 American Heart Association, Inc.
Notes:: This is the accepted manuscript version of the abstract. The final version is available online from American Heart Association at https://dx.doi.org/10.1161/CIR.0000000000001116

Licence:: Terms and Conditions of Use for Oxford University Research Archive

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP